chemotherapy for Ovarian Cancer - Advanced Cancer Care

Overview of Chemotherapy for Ovarian Cancer

Chemotherapy involves the use of powerful drugs to target and destroy rapidly dividing ovarian cancer cells throughout the body. It is typically administered after surgery to eliminate any microscopic disease that may remain. The standard treatment for epithelial ovarian cancer involves intravenous combinations of platinum-based drugs and taxanes, which effectively target high-grade serous tumors, while non-platinum options are used for resistant subtypes.

Types of Chemotherapy for Ovarian Cancer

• •Platinum-Based (Carboplatin/Cisplatin + Paclitaxel/Docetaxel)
  This is the standard first-line treatment for epithelial ovarian cancer, usually given every 3 weeks for a total of 6 cycles.
• •Intraperitoneal (IP) Chemotherapy
  This treatment delivers drugs directly into the abdomen for patients with stage III disease after optimal debulking. IP chemotherapy has been shown to improve survival by about 12 months.
• •Neoadjuvant/Interval Chemotherapy
  This approach involves administering 3-4 cycles of chemotherapy before surgery for patients with unresectable advanced disease, followed by cytoreductive surgery.

When Chemotherapy is Needed

• •After Primary Surgery
  All patients with stage II-IV epithelial ovarian cancers receive adjuvant chemotherapy following debulking surgery to reduce the risk of recurrence by 40-50%. Stage IC high-grade tumors also qualify for this treatment.
• •For Recurrent or Platinum-Resistant Disease
  For platinum-sensitive recurrences, carboplatin and paclitaxel can be reused. In resistant cases, alternative medications like liposomal doxorubicin, topotecan, or weekly paclitaxel may be employed.
• •For Non-Epithelial Ovarian Cancer
  Germ cell tumors are typically treated with BEP (bleomycin, etoposide, and cisplatin). Sex cord-stromal tumors rarely require chemotherapy unless they are advanced.

The Treatment Process

Chemotherapy cycles are usually repeated every 3-4 weeks over a duration of 4-6 months, with each session lasting between 3 to 6 hours. Treatments are administered via an IV port or catheter in outpatient infusion centers. Patients receive pre-medications to prevent nausea and allergic reactions. Blood counts are monitored to manage risks of neutropenia, and dose adjustments or growth factors may be used as necessary. IP therapy involves placing an abdominal catheter to deliver heated drugs, which enhances penetration into the peritoneal cavity.

Benefits and Risks

Get Your Free Cancer Diet Plan & Report Analysis Now on WhatsApp

Talk to experts. Understand your reports. Get a personalized diet plan — all free to start.

Get My Free Plan on WhatsApp

India's First Cancer Care Management Platform

Free to start•Secure & private•No app download needed

Chemotherapy achieves a 70-80% response rate in first-line treatments for platinum-sensitive disease, extending median progression-free survival to 18-21 months when combined with PARP maintenance therapy.

Common side effects include nausea (affecting 90% of patients), hair loss, fatigue, neuropathy, and myelosuppression. Long-term risks may include infertility, premature menopause, and a small risk of secondary leukemia (1-2%).

Aftercare and Recovery

It is important to stay well-hydrated, use antiemetics proactively, and adhere to neutropenic precautions. Skin care is essential to prevent rashes caused by taxanes. Regular bloodwork helps monitor recovery, and high-protein nutritional shakes can help combat weight loss. Engaging in exercise can maintain strength during scans to assess treatment response.

Why Choose Everhope

Everhope Oncology tailors chemotherapy regimens using pharmacokinetic dosing and antiemetic protocols that minimize toxicity. The clinic also integrates IV nutritional therapy to support patients’ performance status during treatment cycles.